Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (99)	8/4/1999 12:17:00 AM
From: Mark L.	Read Replies (2) \| Respond to of 427

Thank you. I'd be curious as to why you don't think ENMD is a good "extended-period" short. I think your comments here would strike at the heart of what a good thinking-man's approach to biotech might be. In other words, the issue is not "could something come along which would validate a price?", but "what is a fair price to discount the risks inherent in Phase trials?" Also, this is the second time you mentioned that you felt that Asensio shorts have too much misinformation floating around. I'd be interested in a clarification of this. It is my impression that actually with Asensio shorts there is an enormous amount of information; it's just that much of it is conflicting. But isn't that a good thing?--you can sort out what you agree with. Bottom line I guess is that if you are looking for wildly overpriced shortable junk, I think you are better off looking among the dot.coms than the biotechs. That's like saying a woman isn't attractive just because she doesn't look like Kim Basinger.